Cargando…
Nuclear iASPP may facilitate prostate cancer progression
One of the major challenges in prostate cancer (PCa) research is the identification of key players that control the progression of primary cancers to invasive and metastatic disease. The majority of metastatic PCa express wild-type p53, whereas loss of p63 expression, a p53 family member, is a commo...
Autores principales: | Morris, E V, Cerundolo, L, Lu, M, Verrill, C, Fritzsche, F, White, M J, Thalmann, G N, ten Donkelaar, C S, Ratnayaka, I, Salter, V, Hamdy, F C, Lu, X, Bryant, R J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649527/ https://www.ncbi.nlm.nih.gov/pubmed/25341046 http://dx.doi.org/10.1038/cddis.2014.442 |
Ejemplares similares
-
Regulation of immunological tolerance by the p53-inhibitor iASPP
por: Akama-Garren, Elliot H., et al.
Publicado: (2023) -
iASPP regulates neurite development by interacting with Spectrin proteins
por: Wang, Junhao, et al.
Publicado: (2023) -
FHL2 interacts with iASPP and impacts the biological functions of leukemia cells
por: Lu, Wenting, et al.
Publicado: (2017) -
Overexpression of iASPP is required for autophagy in response to oxidative stress in choriocarcinoma
por: Chan, Ka-Kui, et al.
Publicado: (2019) -
p53 inhibitor iASPP is an unexpected suppressor of KRAS and inflammation-driven pancreatic cancer
por: Miller, Paul, et al.
Publicado: (2023)